Cargando…

Efficacy of sildenafil and high-dose anakinra in an MIS-C patient with pulmonary vasculitis: A case report

Multisystem inflammatory syndrome in children (MIS-C) is a newly identified clinical entity still not very well known in terms of epidemiology, pathogenesis, and long-term outcome. Pulmonary involvement with acute respiratory failure is an unusual life-threatening complication of MIS-C, often a reas...

Descripción completa

Detalles Bibliográficos
Autores principales: La Torre, Francesco, Calabrese, Gerolmina, Signorile, Katia, Bizzoco, Francesca, Mastrorilli, Carla, Strippoli, Antonella, Amato, Doriana, Carella, Francesco, Vairo, Ugo, Giordano, Paola, Milella, Leonardo, Cardinale, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835840/
https://www.ncbi.nlm.nih.gov/pubmed/36644405
http://dx.doi.org/10.3389/fped.2022.1015617
_version_ 1784868749720944640
author La Torre, Francesco
Calabrese, Gerolmina
Signorile, Katia
Bizzoco, Francesca
Mastrorilli, Carla
Strippoli, Antonella
Amato, Doriana
Carella, Francesco
Vairo, Ugo
Giordano, Paola
Milella, Leonardo
Cardinale, Fabio
author_facet La Torre, Francesco
Calabrese, Gerolmina
Signorile, Katia
Bizzoco, Francesca
Mastrorilli, Carla
Strippoli, Antonella
Amato, Doriana
Carella, Francesco
Vairo, Ugo
Giordano, Paola
Milella, Leonardo
Cardinale, Fabio
author_sort La Torre, Francesco
collection PubMed
description Multisystem inflammatory syndrome in children (MIS-C) is a newly identified clinical entity still not very well known in terms of epidemiology, pathogenesis, and long-term outcome. Pulmonary involvement with acute respiratory failure is an unusual life-threatening complication of MIS-C, often a reason for admission to the pediatric intensive care unit (PICU) and the use of mechanical ventilation. We present a case of a 7-year-old male patient, previously healthy, hospitalized for MIS-C, treated with intravenous immunoglobulins (IVIG), high dose methylprednisolone, and anakinra. After 2 days of the aforementioned therapy, the patient presented with hypoxia (SatO(2): 85% in ambient air room) and breathing difficulties. A chest computed tomography (CT) scan showed the presence of multiple bilateral basal parenchymal thickening and small basal pleural effusion and an arterial blood gas analysis revealed severe hypoxia (PaO(2)/FiO(2) ratio, 170 mmHg). Because of a worsening of respiratory distress, the patient was transferred to the PICU, where invasive mechanical ventilation and a continuous infusion of anakinra (12 mg/kg/day) were started. An echocardiogram was performed, which showed an increase in pulmonary pressure (40 mmHg) with normal heart ejection fraction (55%), and the hypothesis of pulmonary vasculitis involving the pulmonary arterioles was made. Therefore, therapy with sildenafil (0.15 mg/kg/day) was promptly set up, with an immediate improvement of the clinical picture of respiratory failure, reduction of pulmonary pressure (23 mmHg), and subsequent extubation at 36 h with a regular clinical course until discharge. As far as we know, our case represents the first report of pulmonary vasculitis in an MIS-C patient. The use of sildenafil and high-dose continuous anakinra may represent a rescue therapy in cases of MIS-C with pulmonary vasculitis or with difficulty in extubation, allowing a short-term hospitalization in intensive care and improving the long-term outcome in these patients.
format Online
Article
Text
id pubmed-9835840
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98358402023-01-13 Efficacy of sildenafil and high-dose anakinra in an MIS-C patient with pulmonary vasculitis: A case report La Torre, Francesco Calabrese, Gerolmina Signorile, Katia Bizzoco, Francesca Mastrorilli, Carla Strippoli, Antonella Amato, Doriana Carella, Francesco Vairo, Ugo Giordano, Paola Milella, Leonardo Cardinale, Fabio Front Pediatr Pediatrics Multisystem inflammatory syndrome in children (MIS-C) is a newly identified clinical entity still not very well known in terms of epidemiology, pathogenesis, and long-term outcome. Pulmonary involvement with acute respiratory failure is an unusual life-threatening complication of MIS-C, often a reason for admission to the pediatric intensive care unit (PICU) and the use of mechanical ventilation. We present a case of a 7-year-old male patient, previously healthy, hospitalized for MIS-C, treated with intravenous immunoglobulins (IVIG), high dose methylprednisolone, and anakinra. After 2 days of the aforementioned therapy, the patient presented with hypoxia (SatO(2): 85% in ambient air room) and breathing difficulties. A chest computed tomography (CT) scan showed the presence of multiple bilateral basal parenchymal thickening and small basal pleural effusion and an arterial blood gas analysis revealed severe hypoxia (PaO(2)/FiO(2) ratio, 170 mmHg). Because of a worsening of respiratory distress, the patient was transferred to the PICU, where invasive mechanical ventilation and a continuous infusion of anakinra (12 mg/kg/day) were started. An echocardiogram was performed, which showed an increase in pulmonary pressure (40 mmHg) with normal heart ejection fraction (55%), and the hypothesis of pulmonary vasculitis involving the pulmonary arterioles was made. Therefore, therapy with sildenafil (0.15 mg/kg/day) was promptly set up, with an immediate improvement of the clinical picture of respiratory failure, reduction of pulmonary pressure (23 mmHg), and subsequent extubation at 36 h with a regular clinical course until discharge. As far as we know, our case represents the first report of pulmonary vasculitis in an MIS-C patient. The use of sildenafil and high-dose continuous anakinra may represent a rescue therapy in cases of MIS-C with pulmonary vasculitis or with difficulty in extubation, allowing a short-term hospitalization in intensive care and improving the long-term outcome in these patients. Frontiers Media S.A. 2023-01-04 /pmc/articles/PMC9835840/ /pubmed/36644405 http://dx.doi.org/10.3389/fped.2022.1015617 Text en © 2023 La Torre, Calabrese, Signorile, Bizzoco, Mastrorilli, Strippoli, Amato, Carella, Vairo, Giordano, Milella and Cardinale. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
La Torre, Francesco
Calabrese, Gerolmina
Signorile, Katia
Bizzoco, Francesca
Mastrorilli, Carla
Strippoli, Antonella
Amato, Doriana
Carella, Francesco
Vairo, Ugo
Giordano, Paola
Milella, Leonardo
Cardinale, Fabio
Efficacy of sildenafil and high-dose anakinra in an MIS-C patient with pulmonary vasculitis: A case report
title Efficacy of sildenafil and high-dose anakinra in an MIS-C patient with pulmonary vasculitis: A case report
title_full Efficacy of sildenafil and high-dose anakinra in an MIS-C patient with pulmonary vasculitis: A case report
title_fullStr Efficacy of sildenafil and high-dose anakinra in an MIS-C patient with pulmonary vasculitis: A case report
title_full_unstemmed Efficacy of sildenafil and high-dose anakinra in an MIS-C patient with pulmonary vasculitis: A case report
title_short Efficacy of sildenafil and high-dose anakinra in an MIS-C patient with pulmonary vasculitis: A case report
title_sort efficacy of sildenafil and high-dose anakinra in an mis-c patient with pulmonary vasculitis: a case report
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835840/
https://www.ncbi.nlm.nih.gov/pubmed/36644405
http://dx.doi.org/10.3389/fped.2022.1015617
work_keys_str_mv AT latorrefrancesco efficacyofsildenafilandhighdoseanakinrainanmiscpatientwithpulmonaryvasculitisacasereport
AT calabresegerolmina efficacyofsildenafilandhighdoseanakinrainanmiscpatientwithpulmonaryvasculitisacasereport
AT signorilekatia efficacyofsildenafilandhighdoseanakinrainanmiscpatientwithpulmonaryvasculitisacasereport
AT bizzocofrancesca efficacyofsildenafilandhighdoseanakinrainanmiscpatientwithpulmonaryvasculitisacasereport
AT mastrorillicarla efficacyofsildenafilandhighdoseanakinrainanmiscpatientwithpulmonaryvasculitisacasereport
AT strippoliantonella efficacyofsildenafilandhighdoseanakinrainanmiscpatientwithpulmonaryvasculitisacasereport
AT amatodoriana efficacyofsildenafilandhighdoseanakinrainanmiscpatientwithpulmonaryvasculitisacasereport
AT carellafrancesco efficacyofsildenafilandhighdoseanakinrainanmiscpatientwithpulmonaryvasculitisacasereport
AT vairougo efficacyofsildenafilandhighdoseanakinrainanmiscpatientwithpulmonaryvasculitisacasereport
AT giordanopaola efficacyofsildenafilandhighdoseanakinrainanmiscpatientwithpulmonaryvasculitisacasereport
AT milellaleonardo efficacyofsildenafilandhighdoseanakinrainanmiscpatientwithpulmonaryvasculitisacasereport
AT cardinalefabio efficacyofsildenafilandhighdoseanakinrainanmiscpatientwithpulmonaryvasculitisacasereport